Skip to main content

PRO

Stock
Information Technology
Software - Application

Performance overview

PRO Price
Price Chart

Forward-looking statistics

Beta
1.49
Risk
47.43%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

pros (nyse: pro) provides ai-based solutions that power commerce in the digital economy. using artificial intelligence, pros accelerates customers' ability to embrace digital selling and ecommerce channels. with predictive and prescriptive guidance, companies are enabled to dynamically price, configure and sell their products and services across all channels with speed, precision, and consistency. pros customers, who are leaders in their markets, benefit from decades of data science expertise infused into our industry solutions. to learn more, visit pros.com

Company info

SectorInformation Technology
IndustrySoftware - Application
Employees2K
Market cap$1.3B

Fundamentals

Enterprise value$893.1M
Revenue$336.0M
Revenue per employee—
Profit margin-3.81%
Debt to equity-4.62

Security info

ExchangeNyse American
Type of shareCommon Stock
Earnings per share (EPS)-$0.27
Dividend per share—
Revenue per share$7.10
Avg trading volume (30 day)$15M
Avg trading volume (10 day)$19M
Put-call ratio—

Macro factor sensitivity

Growth+0.0
Credit+5.2
Liquidity+0.1
Inflation-2.5
Commodities-0.7
Interest Rates-1.9

Valuation

Dividend yield0.00%
PEG Ratio32.57
Price to sales2.37
P/E Ratio32.57
Enterprise Value to Revenue2.66
Price to book-12.04

Upcoming events

Next earnings dayMay 2, 2025
Next dividend day—
Ex. dividend day—

News

PROK Surges More Than 500% on Upbeat Data From Kidney Cell Therapy Study

Shares of ProKidney jump 515% after its kidney cell therapy shows strong efficacy in a Phase II diabetes-related CKD study.

Zacks Investment Research (July 9, 2025)
Trump's latest tariff threats and the impact on markets, ProKidney stock jumps over 500%

Morning Brief, Market Sunrise anchor Ramzan Karmali breaks down the latest international news for July 9, 2025. President Trump stated on a social media post that tariffs will start being paid on August 1st and that date will not change.

Yahoo Finance (July 9, 2025)
ProKidney: What's Happening With PROK Stock?

ProKidney Corp. (NASDAQ: PROK) has seen significant volatility following encouraging Phase 2 clinical trial outcomes for its REGEN-007 study, which assesses rilparencel in patients suffering from chronic kidney disease (CKD) and diabetes. The study indicated considerable enhancements in kidney function:

Forbes (July 9, 2025)
Gold Falls 1%; ProKidney Shares Spike Higher

U.S. stocks traded mixed midway through trading, with the Dow Jones index dipping more than 150 points on Tuesday.

Benzinga (July 8, 2025)
3 Audio Video Stocks to Consider Amid Industry Headwinds

Amid cautious discretionary spending, investments in cutting-edge and innovative solutions are likely to aid Zacks Audio Video Production industry participants like SONO, GPRO and LVO.

Zacks Investment Research (July 8, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free